Cite
Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects
MLA
Huili Zhou, et al. “Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.” Antimicrobial Agents and Chemotherapy, vol. 65, no. 10, July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e9efc75d2032716907d74ea434a4378c&authtype=sso&custid=ns315887.
APA
Huili Zhou, Duo Lv, Lihua Wu, Meihua Lin, Guolan Wu, You Zhai, Jingzi J Wu, Jing Wu, & Jianzhong Shentu. (2021). Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 65(10).
Chicago
Huili Zhou, Duo Lv, Lihua Wu, Meihua Lin, Guolan Wu, You Zhai, Jingzi J Wu, Jing Wu, and Jianzhong Shentu. 2021. “Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.” Antimicrobial Agents and Chemotherapy 65 (10). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e9efc75d2032716907d74ea434a4378c&authtype=sso&custid=ns315887.